Neurocrine Biosciencesの空売り状況は、投資家がNeurocrine Biosciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Neurocrine Biosciences (NASDAQ:NBIX) 株価情報, 空売り情報

NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

Biotech

News

General

NBIX

Neurocrine Biosciences Announces New Data From Phase 2 Study Of Nbi-1117568 In Adults With Schizophrenia At American Society Of Clinical Psychopharmacology 2025

A large exercise of company stock options by CHARLES KEVIN GORMAN, Board Member at Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) was disclosed in a new SEC filing on May 22, as part of an insider exercise.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000914475/000091447525000132//Archives/edgar/data/914475/000091447525000132/0000914475-25-000132-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that GORMAN, Board Member at Neurocrine Biosciences, a company in the Health Care sector, just exercised stock options worth 0 shares of NBIX stock with an exercise price of $0.0.
Neurocrine Biosciences shares are trading, exhibiting down of 0.0% and priced at $119.12 during Friday's morning. This values GORMAN's 0 shares at $0.
<h3>About Neurocrine Biosciences</h3>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Neurocrine Biosciences: Delving into Financials</h3>
Revenue Growth: Over the 3 months period, Neurocrine Biosciences showcased positive performance, achieving a revenue growth rate of 11.12% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 98.39%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Neurocrine Biosciences's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.08.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.18.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 40.38 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.11 is above industry norms, reflecting an elevated valuation for Neurocrine Biosciences's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 20.18, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000914475">Check Out The Full List Of Neurocrine Biosciences's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY&#x2122; (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, May 16, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429374-1&amp;h=3224598362&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced&nbsp;it will present new data from the Phase 3 CAHtalyst&#x2122; Pediatric study showing lasting reductions in&nbsp;glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429374-1&amp;h=3320559394&amp;u=https%3A%2F%2Fwww.crenessity.com%2F&amp;a=CRENESSITY%E2%84%A2+(crinecerfont)">CRENESSITY&#x2122; (crinecerfont)</a>&nbsp;for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses. Results also showed improvements in clinical outcomes, including body mass index and insulin resistance. These data will be presented at the Pediatric Endocrine Society (PES) 2025 Annual Meeting&nbsp;taking place from May 15-18, 2025, in National Harbor, MD. &nbsp;

Neurocrine Biosciences To Present One-Year Data From Phase 3 CAHtalyst Pediatric Study At PES 2025, Showing Lasting Reductions In Glucocorticoid Doses Who Received CRENESSITY

<ul>
<li>Patients Treated with INGREZZA&#xAE; (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures</li>
<li>Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference</li>
</ul>
SAN DIEGO, May 16, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429144-1&amp;h=3622899937&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429144-1&amp;h=822071139&amp;u=https%3A%2F%2Fwww.ingrezza.com%2F&amp;a=INGREZZA%C2%AE+(valbenazine)+capsules">INGREZZA&#xAE; (valbenazine) capsules</a> reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429144-1&amp;h=3673751604&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-reports-patient-reported-outcome-data&amp;a=KINECT-PRO%E2%84%A2+study">KINECT-PRO&#x2122; study</a> of INGREZZA, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia. The analyses were presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference in Montreal, Canada.

Neurocrine Biosciences Presents New Phase 4 Analysis Showing INGREZZA Improves Function & Quality Of Life In Tardive Dyskinesia Patients

Presents New Data From The Phase 3 CAHtalyst Adult And Pediatric Studies Of CRENESSITY;  Data Showed That A Substantial Proportion Of Pediatric Patients With Classic Congenital Adrenal Hyperplasia Achieved Physiologic-Range Glucocorticoid Doses And Normal Androstenedione Levels

<ul>
<li>Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical Outcomes</li>
<li>Findings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting</li>
</ul>

Events

Neurocrine Biosciences Presents Study Showing Relationship Between Higher Glucocorticoid Dose And Adverse Clinical Outcomes

- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose
- Findings to be Presented at the 2025 Joint Congress of&nbsp;the European Society for Paediatric Endocrinology&nbsp;and the&nbsp;European Society of Endocrinology

Neurocrine Biosciences Announces New Results From Phase 3 CAHtalyst Pediatric Study

Neurocrine Biosciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock is trading higher on Tuesday after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45206088/neurocrine-biosciences-reports-first-quarter-2025-financial-results-and-reaffirms-2025-financial-g" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
The company on Monday reported adjusted EPS of 70 cents, lower than the $1.20 reported a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of 54 cents</a>.
Neurocrine reported sales of $572.6 million compared to $515.3 million a year ago, missing the&nbsp;consensus of $559.3 million.
Ingrezza&#8217;s first-quarter 2025 net product sales were&nbsp;$545 million, representing an 8% year-over-year growth, driven by underlying patient demand, including record new patient starts and improved gross-to-net dynamics.
<ul>
<li>Expanded formulary access for Ingrezza significantly improved coverage to include two-thirds of tardive dyskinesia (TD) and Huntington&#8217;s disease Medicare beneficiaries.</li>
<li>William Blair writes, &#8220;Ingrezza sales for the quarter were more resilient than investors had feared given Part D formulary utilization and Teva Pharmaceutical Industries Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Austedo competition.&#8221;</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44818760/neurocrine-biosciences-positive-crenessity-physician-survey-turns-this-analyst-bullish" rel="noreferrer noopener">Neurocrine Biosciences&#8217; Positive Crenessity Physician Survey Turns This Analyst Bullish</a>
Crenessity first-quarter net product sales were&nbsp;$14.5 million&nbsp;and included 413 total patient enrollment start forms, reflecting strong initial patient demand with approximately 70% reimbursement coverage for dispensed scripts.
Guidance:&nbsp;Neurocrine Biosciences reaffirms its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569079/why-is-neurocrine-biosciences-stock-trading-lower-on-friday" rel="noreferrer noopener">2025 Ingrezza sales guidance</a> of $2.5 billion-$2.6 billion.
Despite headwinds, Ingrezza sales &#8220;avoided a big miss,&#8221; William Blair analyst Myles R. Minter said in a Tuesday research note.
Minter views Ingrezza as &#8220;the gold-standard pharmacotherapy for TD, given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.&#8221; In addition, the company boasts 14 years of potential future patent protection. 
&#8220;We also view the beat from Crenessity as indicative of a strong sales effort, and although early, we are impressed by the early launch metrics and interest in the orphan disease therapy,&#8221; Minter added.
William Blair <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">maintains the Outperform rating</a>.
Other analyst reaction:
<ul>
<li>Needham maintains Neurocrine Biosciences with a Buy, raising the price target from $138 to $139.</li>
<li>Canaccord Genuity maintains Neurocrin with a Buy, raising the price target from $158 to $160.</li>
<li>UBS keeps the Buy rating for Neurocrine, raising the price target from $137 to $152.</li>
<li>BMO Capital maintains Neurocrine with a Market Perform, raising the price target from $96 to $115.</li>
<li>Guggenheim maintains Neurocrine with a Buy, raising the price target from $155 to $165.</li>
</ul>
Price Action: NBIX stock is up 14% at $125.07&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45221957/pasithea-therapeutics-drug-shows-tumor-reduction-in-pancreatic-cancer-strong-early-trial-results" target="_blank" rel="noreferrer noopener">Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results</a></li>
</ul>

Analyst Color

Earnings

Guidance

Health Care

Price Target

Analyst Ratings

Movers

TEVA

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

Piper Sandler analyst David Amsellem reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and lowers the price target from $160 to $154.

Reiteration

Piper Sandler Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $154

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and raises the price target from $137 to $145.

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $145

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $155 to $165.

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165

U.S. stocks were lower, with the Nasdaq Composite falling over 1% on Tuesday.
Shares of FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) rose sharply during Tuesday's session after the company announced it entered into a definitive agreement to be acquired by AMETEK for an enterprise value of <a href="https://www.benzinga.com/quote/FARO">approximately $920 million</a>.
FARO Technologies shares jumped 34.1% to $42.18 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 42% to $132.09.</li>
<li>Diversified Healthcare Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>) rose 28% to $2.80 after the company reported first-quarter financial results and beat its FFO and sales estimates.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) gained 28% to $3.55 after the company reported better-than-expected first-quarter sales results and issued FY25 sales guidance with its midpoint above estimates.</li>
<li>ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) rose 25.4% to $5.57 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance.</li>
<li>Ameresco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) gained 18% to $13.72 after the company reported better-than-expected quarterly financial results and issued FY25 guidance with its midpoint above estimates.</li>
<li>Lindblad Expeditions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) rose 17.5% to $10.72 after the company reported a first-quarter sales beat and issued FY25 sales guidance with its midpoint above estimates.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) gained 12.8% to $123.73 after the company reported better-than-expected first-quarter financial results. Also, Needham maintained a Buy rating on the stock and raised its price target from $138 to $139.</li>
<li>Hims &amp; Hers Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NASDAQ">HIMS</a>) rose 6.2% to $44.49 after the company reported first-quarter financial results. Also, the company issued second-quarter revenue guidance below estimates.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) gained 7.2% to $48.01 following upbeat quarterly results.</li>
<li>Avient Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) rose 6.4% to $36.19 following quarterly results.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares climbed 6.4% to $27.27 after the company reported better-than-expected quarterly financial results.</li>
<li>Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) rose 6.4% to $36.41 following strong quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

AMRC

ARMK

AVNT

EVGO

FARO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LIND

TDUP

FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Market Perform and raises the price target from $96 to $115.

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $115

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $137 to $152.

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $152

Ratings for Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $162.95, with a high estimate of $185.00 and a low estimate of $137.00. This current average has decreased by 4.65% from the previous average price target of $170.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532832_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$168.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$137.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$184.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$179.00</td>
<td>$184.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Neurocrine Biosciences: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 19 Analyst Ratings Have To Say About Neurocrine Biosciences

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $158 to $160.

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160

WIIM

Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Needham maintained a Buy rating on the stock and raised its price target from $138 to $139.

Needham analyst Ami Fadia maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $138 to $139.

Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $139

<h3>Gainers</h3>
<ul>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) shares increased by 21.7% to $1.74 during Monday's after-market session. The market value of their outstanding shares is at $63.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 17.73% to $1.66. The market value of their outstanding shares is at $22.8 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) shares moved upwards by 14.45% to $16.31. The market value of their outstanding shares is at $693.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares rose 11.79% to $122.7. The market value of their outstanding shares is at $12.2 billion. The company's, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock increased by 11.76% to $0.19. The market value of their outstanding shares is at $4.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 11.27% to $0.21. The market value of their outstanding shares is at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 22.2% to $0.86 during Monday's after-market session. The company's market cap stands at $5.1 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock declined by 15.0% to $11.85. The company's market cap stands at $280.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.24% to $0.85. The market value of their outstanding shares is at $60.7 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) stock decreased by 8.13% to $30.54. The market value of their outstanding shares is at $932.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 8.12% to $3.01. The market value of their outstanding shares is at $78.3 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 8.05% to $67.99. The company's market cap stands at $7.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

CTOR

GCTK

HSTM

NCNA

OGEN

SIBN

SNTI

SXTC

TCMD

12 Health Care Stocks Moving In Monday's After-Market Session

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.54 by 29.63 percent. This is a 41.67 percent decrease over earnings of $1.20 per share from the same period last year. The company reported quarterly sales of $572.60 million which beat the analyst consensus estimate of $559.33 million by 2.37 percent. This is a 11.12 percent increase over sales of $515.30 million the same period last year.

Earnings Beats

Neurocrine Biosciences Q1 Adj. EPS $0.70 Beats $0.54 Estimate, Sales $572.60M Beat $559.33M Estimate

Press Releases

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Comments

Neurocrine Biosciences

空売り

Neurocrine Biosciences (NASDAQ:NBIX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル